Researchers report that IFI35 can block hepatitis B virus persistence by degrading HNF4α, a transcriptional regulator required for HBV cccDNA transcription. The study described IFI35 as part of an innate immune circuit that turns on antiviral alarm responses while simultaneously cutting off the host-factor pathway HBV uses to sustain gene expression. If validated across broader models and clinical biomarkers, this approach represents a host-directed option that aims to suppress viral transcription without relying solely on polymerase inhibition. It also adds to the growing interest in “functional cure” mechanisms that target covalently closed circular DNA activity. For HBV developers, the data highlight a mechanism-adjacent route—intervening in host transcriptional support—that could complement existing therapies and potentially reduce residual viral transcription activity.